The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

Gilead Sciences Inc. closed 8.32% below its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...

The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...

Gilead is laying off 36 people as part of a rethink that saw the Big Pharma scrap plans to expand a biologics facility in ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. Nevertheless, the company suffered a significant setback after the US Food and Drug Administration put on hold ...

The Impax US Sustainable Economy Fund underperformed the Russell 1000 benchmark in the first quarter. Read more here.

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

Margaret Atwood’s chilling world of Gilead returns in The Testaments, the long-anticipated sequel to her groundbreaking novel ...

The firm’s analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the ...

Let’s just say you wake up one morning in The Handmaid’s Tale universe, stuck inside the color-coded hellscape that is Gilead ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...